Complete Genomics Inc. yesterday filed for an initial public offering that could be worth up to $96.6 million, and if the popularity of a competing genome sequencing company’s stock is an indicator for its success, Complete Genomics won’t have much trouble hitting its mark.
Pacific Biosciences of California Inc. (NSDQ:PACB) entered the market today and raised $200 million in its IPO. The company is working on a whole-genome sequencing device that would deliver "real-time" observation of DNA-related processes.